Copyright
©The Author(s) 2024.
World J Hepatol. Aug 27, 2024; 16(8): 1131-1144
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1131
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1131
Table 5 Univariable Cox proportional hazard regression survival analysis
OS | RFS | |||
Variable | HR (95%CI) | P value | HR (95%CI) | P value |
Age (years), ≥ 49 vs < 49 | 1.06 (0.77-1.47) | 0.72 | 1.01 (0.71-1.44) | 0.97 |
Gender, male vs female | 0.93 (0.64-1.35) | 0.68 | 0.89 (0.59-1.32) | 0.55 |
Race, Han vs others | 0.95 (0.69-1.31) | 0.76 | 0.80 (0.58-1.32) | 0.27 |
Smoking, yes vs no | 0.70 (0.48-1.03) | 0.07 | 0.57 (0.36-0.89) | 0.01 |
Drinking, yes vs no | 0.74 (0.51-1.07) | 0.11 | 0.63 (0.41-0.96) | 0.03 |
HBV, positive vs negative | 1.22 (0.86-1.74) | 0.27 | 1.48 (0.99-2.19) | 0.05 |
HCV, positive vs negative | 0.85 (0.56-1.30) | 0.46 | 0.97 (0.62-1.50) | 0.89 |
AFP, positive vs negative | 2.93 (2.03-4.24) | 1.18 × 10-8 | 2.63 (1.75-3.95) | 3.04 × 10-6 |
AFB1 exposure, high vs low | 3.00 (2.06-4.36) | 8.43 × 10-9 | 3.41 (2.25-5.18) | 8.67 × 10-9 |
Tumor size (cm), > 5 vs ≤ 5 | 2.70 (1.85-3.93) | 2.63 × 10-7 | 2.50 (1.65-3.77) | 1.37 × 10-5 |
ES grade, III-IV vs I-II | 1.79 (1.29-2.49) | 5.55 × 10-4 | 1.60 (0.79-2.30) | 0.01 |
TNM stage, II vs I | 1.57 (0.97-2.53) | 0.06 | 1.35 (0.79-2.30) | 0.27 |
TNM stage, III vs I | 5.95 (3.56-9.94) | 1.01 × 10-11 | 4.29 (2.48-7.41) | 1.92 × 10-7 |
Liver cirrhosis, yes vs no | 1.02 (0.72-1.44) | 0.93 | 1.17 (0.79-1.74) | 0.43 |
MVD, high vs low | 2.87 (2.06-4.02) | 6.84 × 10-10 | 3.40 (2.34-4.96) | 1.82 × 10-10 |
PVTT, positive vs negative | 2.30 (1.62-3.28) | 4.06 × 10-6 | 2.43 (1.68-3.53) | 2.95 × 10-6 |
MVI, positive vs negative | 2.48 (1.75-3.50) | 2.56 × 10-7 | 2.53 (1.76-3.64) | 5.63 × 10-7 |
TIMP3, LTE vs HTE | 2.92 (2.19-4.09) | 4.10 × 10-10 | 2.34 (1.63-3.38) | 4.80 × 10-6 |
-
Citation: Liang QJ, Long QQ, Tian FQ, Su QY, Zhu XY, Long XD. Tissue inhibitor of metalloproteinase-3 expression affects clini
copathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma. World J Hepatol 2024; 16(8): 1131-1144 - URL: https://www.wjgnet.com/1948-5182/full/v16/i8/1131.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i8.1131